Actelion Pharmaceuticals Ltd, a Swiss specialist in drugs for pulmonary arterial hypertension (PAH), has reported positive data from a Phase 3 trial for a new PAH agent that support the company’s quest to extend its franchise in this area. ---Subscribe to MedNous to access this article--- Company News
